RxDoctor Payments Data

Bart Chess, MD

Vascular Surgery · Pittsburgh, PANPI 1023037413

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.1%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 32.1% of the total. 2025 is the largest year on record at $5,216, 5.6 times the $929 reported in 2019.

$11,101in general payments, 2019–2025

Across 99 payments — averaging $112.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$4K
  • Medtronic$3K
  • Terumo Medical Corporation$1K
  • Silk Road Medical, Inc.$1K
  • Boston Scientific$892
  • Endologix LLC$627
  • plus $927 from 7 others
$126,178in ownership & investment interests, 2019–2025

Across 5 payments — averaging $25,236 each. An ownership or investment interest held by the physician or an immediate family member.

  • Centerline Biomedical Inc.$126K

What the payments were for

  • Grants$7006%
  • Travel & lodging$4,06637%
  • Food & beverage$6,33557%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,101 in reported general payments places this provider in the 75th percentile of 236 vascular surgery providers in Pennsylvania.

See all vascular surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$133,777
Medicare patients
442
Services billed
881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban48$58,187
EliquisApixaban33$44,380
ClopidogrelClopidogrel Bisulfate163$1,403
Enoxaparin Sodium15$1,062
Cilostazol30$598
Atorvastatin Calcium40$587
Gabapentin29$324
Warfarin Sodium16$174
Prednisone18$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$78$58,18748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 236 vascular surgery providers in Pennsylvania.

Other vascular surgery in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →